Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Keryx Biopharmaceuticals Fell 18% in October

By Brian Feroldi – Nov 9, 2016 at 5:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares were hit hard by the general sell-off in the biotech sector.

Image source: Getty Images.

What happened

Shares of Keryx Biopharmaceuticals (KERX), a commercial-stage company focused on renal disease, fell by 18% during the month of October, according to data from S&P Global Market Intelligence.

KERX Chart

KERX data by YCharts.

So what

Given the huge drop, you might assume that something bad happened to the company, but that doesn't appear to be the case. The only press release to come out of Keryx in October was to announce that it would be presenting data at the upcoming American Society of Nephrology Kidney Week in November.

Given the lack of news, it is likely that Keryx simply got caught up in the general biotech sell-off.

Here's a look at Keryx's monthly stock performance compared to SPDR S&P Biotech ETF (XBI 0.64%).

KERX Chart

KERX data by YCharts.

As you can see, the two roughly traded in tandem during October. In addition, it is worth remembering that shares of Keryx actually rose 28.6% in September. Against that backdrop, it is easy to understand why shares slumped.

Now what

Keryx is set to report its third-quarter results on Wednesday, Nov. 9. This will be a great chance for investors to learn how healthcare providers are responding to the company's manufacturing issues.

For what it is worth, analysts are expecting that the company's results will be rough. Current projections call roughly $5.3 million in total sales, which, if true, would represent a steep drop from the $9.3 million that was recorded in the second quarter.

Looking beyond the numbers, shareholders will want to listen in on the company's conference call to see if management still believes that the manufacturing issues will be completely resolved before year's end. Until we know more, the smart move is to remain cautious.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.